Recruiting

Testing two medications together for advanced cervical cancer

Plain-English translation of NCT04865887 on ClinicalTrials.gov ↗ · Source last updated October 2025 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether two medications used together— and —can help patients with advanced cervical cancer. works by helping your immune system recognize and fight cancer cells, while blocks proteins that help tumors grow. Researchers want to see if combining these medications is effective and safe for people whose cancer has progressed despite previous treatment.

Cervical cancer that has spread to other parts of the body or cannot be removed with surgery is difficult to treat, and many patients do not respond well to standard chemotherapy alone. This trial is exploring whether this medication combination might offer a new treatment option for people who have already tried at least one other therapy without success.

Do you qualify?

You likely qualify if…

you are a woman at least 18 years old
you have been diagnosed with cervical cancer that is locally advanced or has spread to other parts of your body
your cancer has either gotten worse or stopped responding to at least one previous treatment, or you could not tolerate that treatment
you have measurable tumors that can be seen on scans
you are healthy enough for treatment (measured by your overall physical condition and blood work)
you are not pregnant or breastfeeding, and if you could become pregnant, you agree to use contraception during and for 4 months after treatment

You likely don't qualify if…

you have received prior immunotherapy drugs that work on PD-1 or PD-L1 pathways
you are pregnant or have a positive pregnancy test within 72 hours of starting treatment
you have received other cancer treatments within the past 4 weeks
your blood counts, kidney function, or liver function are not within safe ranges

What participation looks like

You would take the medication combination regularly as prescribed at home while attending scheduled clinic visits for monitoring. The trial uses a two-stage design: if the treatment shows promise in the first 11 patients, it will enroll up to 24 additional patients for a total of 35. You would have regular blood tests and imaging scans to measure whether your cancer is responding to the treatment.

AI-generated summary from trial data · Jul 6, 2026 · Not medical advice

Trial locations(4 sites)

United States

MedStar Georgetown University Hospital, Washington D.C., District of Columbia

Medstar Washington Hospital Center, Washington D.C., District of Columbia

Georgia Cancer Center at Augusta University, Augusta, Georgia

John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey